Imperatorin and β-sitosterol have synergistic activities in alleviating collagen-induced arthritis.


Journal

Journal of leukocyte biology
ISSN: 1938-3673
Titre abrégé: J Leukoc Biol
Pays: England
ID NLM: 8405628

Informations de publication

Date de publication:
08 2020
Historique:
received: 27 11 2019
revised: 14 03 2020
accepted: 22 03 2020
pubmed: 12 5 2020
medline: 15 12 2020
entrez: 12 5 2020
Statut: ppublish

Résumé

Rheumatoid arthritis (RA) is a chronic disease with complex molecular network of pathophysiology, single drug is usually not full satisfactory because it is almost impossible to target the whole molecular network of the disease. Drug combinations that act synergistically with each another is an effective strategy in RA therapy. In this study, we aimed to establish a new strategy to search effective synergized compounds from Chinese herbal medicine (CHM) used in RA. Based on multi-information integrative approaches, imperatorin (IMP) and β-sitosterol (STO) were predicted as the most effective pair for RA therapy. Further animal experiments demonstrated that IMP+STO treatment ameliorated arthritis severity of collagen-induced arthritis (CIA) rats in a synergistic manner, whereas IMP or STO administration separately had no such effect. RNA sequencing and IPA analysis revealed that the synergistic mechanism of IMP+STO treatment was related to its regulatory effect on 5 canonical signaling pathways, which were not found when IMP or STO used alone. Moreover, LTA, CD83, and SREBF1 were 3 important targets for synergistic mechanism of IMP+STO treatment. The levels of these 3 genes were significantly up-regulated in IMP+STO group compared to model group, whereas IMP or STO administration separately had no effect on them. In conclusion, this study found that IMP and STO were 2 synergistic compounds from the CHM in RA therapy, whose synergistic mechanism was closely related to regulate the levels of LTA, CD83, and SREBF1.

Identifiants

pubmed: 32392637
doi: 10.1002/JLB.3MA0320-440RR
pmc: PMC7496114
doi:

Substances chimiques

Drugs, Chinese Herbal 0
Furocoumarins 0
Sitosterols 0
gamma-sitosterol 5LI01C78DD
imperatorin K713N25C78

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

509-517

Informations de copyright

© 2019 The Authors. Journal of Leukocyte Biology published by Wiley Periodicals, Inc. on behalf of Society for Leukocyte Biology.

Références

Tissue Antigens. 2006 Jan;67(1):57-60
pubmed: 16451202
Arthritis Res. 2000;2(5):374-8
pubmed: 11094451
Cytokine. 2017 Aug;96:1-7
pubmed: 28267648
Nat Chem Biol. 2008 Nov;4(11):682-90
pubmed: 18936753
Arthritis Rheum. 2005 Dec;52(12):3755-60
pubmed: 16320326
J Pharmacol Exp Ther. 2011 Oct;339(1):72-81
pubmed: 21730010
Arthritis Rheum. 2003 Dec;48(12):3568-83
pubmed: 14674010
Lancet. 2013 Feb 9;381(9865):451-60
pubmed: 23294500
Nat Rev Endocrinol. 2017 Dec;13(12):710-730
pubmed: 28849786
Molecules. 2014 Oct 30;19(11):17649-62
pubmed: 25361427
Arthritis Res Ther. 2004;6(3):R282-94
pubmed: 15142275
Evid Based Complement Alternat Med. 2014;2014:138460
pubmed: 24707305
Front Pharmacol. 2017 May 03;8:230
pubmed: 28515692
Arthritis Res Ther. 2011 Jul 26;13(4):232
pubmed: 21861866
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
Bioinformatics. 2014 Apr 15;30(8):1190-1192
pubmed: 24389658
J Cell Mol Med. 2016 Dec;20(12):2231-2240
pubmed: 27605177
Trends Pharmacol Sci. 2015 Apr;36(4):189-95
pubmed: 25732812
Sci Rep. 2016 Mar 03;6:22602
pubmed: 26935797
Inflamm Res. 2018 Jun;67(6):495-501
pubmed: 29541795
Arthritis Res Ther. 2013;15(6):R202
pubmed: 24283517
J Clin Invest. 2002 May;109(9):1125-31
pubmed: 11994399
J Leukoc Biol. 2020 Aug;108(2):509-517
pubmed: 32392637
Bioinformatics. 2013 Apr 15;29(8):1092-4
pubmed: 23493324
Lancet. 2014 Jan 25;383(9914):321-32
pubmed: 24168956
Genome Biol. 2007;8(9):R183
pubmed: 17784955
Nucleic Acids Res. 2014 Jul;42(Web Server issue):W130-6
pubmed: 24875471
Clin Ter. 2015;166(3):e197-202
pubmed: 26152632

Auteurs

Qingqing Guo (Q)

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.

Li Li (L)

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.

Kang Zheng (K)

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.

Guang Zheng (G)

School of Information Science & Engineering, Lanzhou University, Lanzhou, Gansu, China.

Haiyang Shu (H)

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.

Yingjie Shi (Y)

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Cheng Lu (C)

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.

Jun Shu (J)

Institute of Clinical Medical Science, China-Japan Friendship Hospital, Beijing, China.

Daogang Guan (D)

Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southern Medical University, and Guangdong Provincial Key Laboratory of Single Cell Technology and Application, Guangzhou, Guangdong Province, China.
Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.

Aiping Lu (A)

Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Xiaojuan He (X)

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH